Eikon Therapeutics, a publicly owned company headquartered in the United States, was founded in 2019 and reported $0.0 in revenue as of 2025. The biopharmaceutical company applies super-resolution fluorescence microscopy, advanced engineering, and high-performance computing to measure protein dynamics in living cells. It leverages these single-molecule tracking technologies to discover and develop targeted small-molecule therapies for oncology and neurological disorders.
Subscribe for full access to Eikon Therapeutics's products in full detail 
